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Reply
The points made in the letter do not contradict our data. Ad-
vanced glycation end products (AGEs) are a heterogeneous group.
Non-carboxymethyllysine (CML) AGEs may influence the develop-
ment of abdominal aortic aneurysms (AAAs), and assessing concen-
trations of cross-linking AGEs like pentosidine will be important. We
did not claim that our study provided conclusive evidence—merely
that the data suggested that accelerated advanced glycation might
explain the inverse association between diabetes and AAA. We had
also acknowledged that othermarkers of the glycation pathwaywould
need to be examined in future studies.
The assessment of any putative biomarker at tissue level is
always desirable, and sometimes preferable. However, this is not
without problems in AAA, because only tissue samples from end-
stage disease (ie, large AAAs) with secondary degenerative changes
are available. Furthermore, such samples are becoming scarce due
to the increasing role of endoluminal stenting. We are also unsure
about whether the findings in the three cited studies in hemodial-
ysis patients are generalizable to the vast majority of patients with
normal or mildly impaired renal function.
Despite the acknowledged limitations of our study, CML is used
as a general and reproducible measure of glycation, and our data are
consistent with evidence that glycation of the extracellular matrix
inhibits degradationbothbydeactivatingmacrophages and increasing
the resistance of the extracellular matrix to degradation.1
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Regarding “Statins, heme oxygenase-1, iron, and
atherosclerosis”
DePalma et al1 described interactions of serum ferritin with
statin use in a substudy of the iron (Fe) and atherosclerosis study
(FeAST). At baseline, 53 participants on statins had slightly
lower mean entry-level ferritin values (1l4.06 ng/mL) vs the 47
off statins (127.62 ng/mL). Longitudinal analysis of follow-up
data, after adjusting for the phlebotomy treatment effect,
showed that statin use was associated with significantly lower
ferritin levels (–29.78 ng/mL; Cohen effect size, 0.47 [tdf,
134  2.33, P  .02]).
Statins induce heme oxygenase-1 (HO1)2,3 the rate limiting
enzyme involved in heme catabolism. Heme catabolism is a key
process in mobilizing macrophage iron derived from ingested
erythrocytes. Alterations in the activity of HO1 influence the rate
of clearance of hemoglobin-derived iron from macrophages. Phar-
macologic inhibition of HO1 is associated with marked elevation
in serum ferritin without significant changes in several other acute
phase reactants.4 In normal subjects, serum ferritin rose by approx-
imately fourfold within 2 days of administration of Sn mesopor-
phyrin, an HO1 inhibitor.4
In the HO1 deficient mouse (HO1/), conspicuous iron
loading is seen in Kupffer cells, hepatocytes, hepatic vascular
tissue, and renal cortical tubules.5 In another study of
HO1/ mice, increased levels of reactive oxygen species
production in macrophages and increased atherosclerotic
plaque were thought to be a result of relatively decreased
intracellular levels of biliverdin or bilirubin, or increased intra-
cellular levels of iron stores.6
In diabetic humans, HO1 promoter polymorphisms caus-
ing weaker upregulation of the enzyme are associated with both
increased cardiovascular disease and significantly increased se-
rum ferritin.7,8 It has been proposed that statins may stabilize
atherosclerotic plaques in part by inducing intralesional HO1,
facilitating iron mobilization, and lowering plaque iron lev-
els.9,10 The findings of DePalma et al1 are compatible with this
proposed mechanism.
Statins have also been reported to lower interleukin-6
(IL-6) concentrations.11 IL-6 is a potent inducer of hepcidin
which favors iron retention in the macrophage. This effect of
statins is another potential mechanism for lowering iron levels in
plaque macrophages, a process proposed to inhibit atherogen-
esis.10
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Dr Sullivan’s insights and Dr Zacharski’s energetic implemen-
tation of Veteran’s Affairs Cooperative Study Trial 410 stimulated
our biomarker substudy in the Sierra Nevada Health Care cohort
of patients with symptomatic peripheral arterial disease. Dr Sulli-van now suggests mechanisms to account for interactions of iron
and statins associated with interleukin-6 (IL-6) elevations
which we found to be related to iron levels in clinically stable
participants. We might conjecture that iron overload itself
stimulates inflammatory responses and leukocyte activity for
which IL-6 is the biomarker. The statin findings resulted from
increasing use of these agents during the 6-year iron (Fe) and
atherosclerosis study (FeAST) trial.
Our findings of associations between elevated ferritin levels
and inflammatorymarkers, particularly IL-6 andmortality, support
the need for further well powered trials of the iron hypothesis.
These would test the effects of robust, continued iron reduction,
ie, 17 to 25 ng/mL ferritin levels as suggested by Sullivan’s
original observations of levels in menstruating women.1 The ef-
fects of inflammatory biomarkers, hepcidin levels, oxidative
biomarkers, and serial changes in plaque morphology could be
characterized and related to mortality outcomes. Asymptomatic
carotid plaque, studied in the Bruneck studies,2,3 appear to be a
desirable starting point to parse out the effects of iron reduction
strategies on established disease. More work is required to further
examine the relationships of the inflammatory effects of iron upon
atherosclerosis and the possible interactions of iron at the nexus of
statin action mechanisms that reduce inflammation.
We thank Dr Sullivan for his comments and the VA
Sierra Nevada Network’s support of this substudy.
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